Novartis Reports Results of Extended Follow-up P-III COMBI-AD Trial of Tafinlar (dabrafenib) + Mekinist (trametinib) during ESMO18
Shots:
- The P-III COMBI-AD trial involves assessing of Tafinlar (150mg bid) + Mekinist (2mg qd) vs PBO in 438 patients with BRAF V600-mutant stage III Melanoma for 44 months and 42 months respectively
- During the extended follow-up cure rate was 54% vs 37%
- P-III COMBI-AD trial results: RFS rate @ 44 &42 mos. (59%- 54% vs 40%- 38%); patients with no relapse (54% vs 37%); risk of disease recurrence or death by 53%. RFS@ 1- 2- 3- 4yrs.- (88%- 67%- 59%- 54% vs 56%- 44%- 40%- 38%) respectively
- Tafinlar + Mekinist used for targeting multiple kinases in serine/threonine kinase family-BRAF & MEK1/2 and the combination is currently approved in 60 countries
/ article | Ref: Novartis | Image: Financial Times
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com